It regulates migration and invasion in breast cancer through MyoGEF–Cdc42–MMP9 signaling, facilitates ECM remodeling via interactions with neuropilin-1 and α5β1 integrin, and sustains receptor trafficking in glioma and melanoma. This evidence concerns the gene MMP9 and breast cancer.